



COVID-19 Variant Surveillance Report

Week ending August 21, 2021 (MMWR week 33)


Variant Surveillance- Cumulative Summary

| Lineage (WHO Classification) | Proportion of Variant Sequenced | Proportion of Variant | | | | |
|---------------------------------------|---------------------------------|-------------------------------|--|--|--|--|
| | from Dec 20, 2020 (%) | Sequenced in last 4 weeks (%) | | | | |
| Variant of Concern | | | | | | |
| B.1.1.7 (Alpha) | 31.6% | 0.3% | | | | |
| B.1.617.2 (Delta) [§] | 21.4% | 98.1% | | | | |
| AY.2 (Delta) | 0.0% | 0.1% | | | | |
| AY.1 (Delta) | 0.0% | 0.2% | | | | |
| P.1 (Gamma) | 2.0% | 0.2% | | | | |
| B.1.351 (Beta) | 0.1% | 0.0% | | | | |
| Variant of Interest | | | | | | |
| B.1.526 (lota) | 19.6% | 0.0% | | | | |
| B.1.526.1 | 2.7% | 0.0% | | | | |
| B.1.427, B.1.429 (Epsilon)* | 1.1% | 0.0% | | | | |
| B.1.525 (Eta) | 0.2% | 0.0% | | | | |
| P.2 (Zeta) | 0.1% | 0.0% | | | | |
| B.1.617 | 0.1% | 0.0% | | | | |
| B.1.617.1 (Kappa) | 0.1% | 0.0% | | | | |
| Other Lineages | 21.1% | 1.1% | | | | |
| Total Number of Specimens Sequenced** | 17767 | 2221 | | | | |

[§] Delta includes B.1.617.2 and AY.1- AY.12 variants. As of August 23, 2021, AY.3 - AY.12 variants are aggregated with B.1.617.2.

For CDC definitions of variant of concern and variant of interest visit: https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern

COVID-19 Variant Surveillance by Specimen Collected Week- Cumulative Summary




Percentages represent the proportion found in the specified variant lineage. "Other" represents 158 additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

^{**} Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

^{*}Specimens collected 8/15/2021 – 8/21/2021 reflects data for one week with a total of 347 specimens.

COVID-19 Variant Surveillance by State Region- Previous 4 weeks Summary*



Variant Details

| WHO Label | Name (Pango Lineage) | First Detected | CDC Variant Classification | WHO Label |
|-----------|-------------------------|----------------|----------------------------|-----------|
| Alpha | B.1.1.7 | United Kingdom | Variant of Concern | Alpha |
| Beta | B.1.351 | South Africa | Variant of Concern | Beta |
| Delta | B.1.617.2, AY.1 – AY.12 | India | Variant of Concern | Delta |
| Gamma | P.1 | Brazil | Variant of Concern | Gamma |
| Epsilon | B.1.427, B.1.429 | USA-California | Variant of Interest | Epsilon |
| Eta | B.1.525 | USA-New York | Variant of Interest | Eta |
| lota | B.1.526 | USA-New York | Variant of Interest | lota |
| | B.1.526.1 | USA-New York | Variant of Interest | |
| Zeta | P.2 | Brazil | Variant of Interest | Zeta |
| | B.1.617 | India | Variant of Interest | |
| Карра | B.1.617.1 | India | Variant of Interest | Карра |

*Each regional chart represents the proportion of the specified variant lineage and is based on sequencing results from the 4 weeks prior to the week of August 21, 2021. There is an approximately 14-24-day time lag between specimen collection and report of sequencing results to NJDOH. "Other" represents additional lineages which include other COVID-19 variants not classified as variants of concern or variants of interest.

Includes all sequencing results reported by Commercial Labs (LabCorp, Aegis Sciences Corporation, Infinity Biologix and Quest Diagnostics) and the State Public Health Lab that have been submitted for surveillance purposes.

Data reported is based on a subset of sampled specimens from NJ residents sequenced for COVID-19 variant surveillance.